Elismetrep
Small moleculeexperimental
Clinical trial activity
11 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2015 (NCT02429102)
Timeline
Indications
Mechanism of action
TRPM8 inhibitor
Transient receptor potential cation channel subfamily M member 8 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)c1ccc(S(=O)(=O)N(Cc2ccc(OC(F)(F)F)cc2)c2ncc3ccccc3c2C2CC2)cc1- Mol. weight
- 542.54 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3682589 ↗
Also known as
- mt-8554
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06848075 | Phase 2 | Mar 5, 2025 | Kallyope Inc. |
| NCT05123196 | Phase 2 | Nov 30, 2021 | Mitsubishi Tanabe |
| NCT03471130 | Phase 1 | Apr 23, 2018 | Mitsubishi Tanabe |
| NCT03541200 | Phase 2 | Apr 18, 2018 | Mitsubishi Tanabe |
| NCT03381404 | Phase 1 | Dec 19, 2017 | Mitsubishi Tanabe |
| NCT03291067 | Phase 2 | Oct 9, 2017 | Mitsubishi Tanabe |
| NCT03172598 | Phase 2 | Jul 1, 2017 | Mitsubishi Tanabe |
| NCT02803268 | Phase 1 | Jun 1, 2016 | Mitsubishi Tanabe |
| NCT02675309 | Phase 1 | Feb 1, 2016 | Mitsubishi Tanabe |
| NCT02536209 | Phase 1 | Aug 1, 2015 | Mitsubishi Tanabe |
| NCT02429102 | Phase 1 | Apr 1, 2015 | Mitsubishi Tanabe |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mitsubishi Tanabe | For profit | 10 | 10 | 2 | 2015 |
| Kallyope Inc. | For profit | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1